Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

The primary results report of NCT01179048. Its numbers are set against the trial’s posted results below.

What the trial testedrandomised · 9,340 people · 2016

Randomised comparison

Doesn’t vote: same as the registry's posted result, which counts instead

−15%−26% to −3%

Bigger than 5 in 10 for all-cause mortality

As reported

HR 0.85, 95% CI 0.74–0.97 · the paper's word: All-cause mortality

Same as the trial’s posted resultThis paper HR 0.78 (0.66–0.93)Posted HR 0.78 (0.66–0.93)Time From Randomisation to Each Individual Component of the Expanded Composite Cardiovascular Outcome
Same as the trial’s posted resultThis paper HR 0.85 (0.74–0.97)Posted HR 0.85 (0.74–0.97)Time From Randomisation to All Cause Death
Same as the trial’s posted resultThis paper HR 0.87 (0.78–0.97)Posted, primary outcome HR 0.87 (0.78–0.97), p <0.001Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)

the abstract, start to end

… group (447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97; P=0.02).

← favours treatmentfavours comparator →

could be chance

All-cause mortality

HR 0.850.74–0.97

GLP-1 receptor agonistsAll-cause mortality

1 / 3

2016

…

2026

this paperpooled ittrialcites it